^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 negative + AR positive + ER positive

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; ESR1, Era, ESR, NR3A1, ER, ER beta; AR, AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1, Androgen receptor
    Entrez ID:
    2064; 2099; 367
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Associations

    News

    Trials
    5d
    ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer (clinicaltrials.gov)
    P1, N=46, Completed, Ono Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • letrozole • BMS-986310
    5d
    Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant
    5d
    Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial) (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, IceCure Medical Ltd.
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    7d
    KEYNOTE-242: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=1155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2027 --> Aug 2026 | Trial primary completion date: May 2027 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab)
    9d
    Interplay of the IGFBP-3 polymorphism and serum levels of IGF-1/IGFBP-3 with hormone receptor subtypes in patients with breast cancer among Palestinian women. (PubMed, PLoS One)
    These findings suggest that IGF-1 and IGFBP-3 may have potential as candidate biomarkers for breast cancer risk and progression. Integrating genetic, biochemical, and hormone receptor status provides novel insights into breast cancer biology and may support future research on personalized prevention and treatment strategies, particularly in resource-limited settings such as the Gaza Strip.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    15d
    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
    P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: May 2026 --> Sep 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive
    |
    methotrexate IV
    19d
    TIBET: TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=52, Completed, Borstkanker Onderzoek Groep | Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> May 2026
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Lonsurf (trifluridine/tipiracil)
    22d
    An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (clinicaltrials.gov)
    P2, N=40, Recruiting, Fudan University | N=20 --> 40
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    fulvestrant
    23d
    Distribution and molecular drivers of the 21-gene recurrence score in early breast cancer with low, intermediate, and high estrogen receptor expression. (PubMed, Front Immunol)
    RS was only moderately correlated with proliferation features and minimally determined by any of the four module components in ER-low tumors. These findings are exploratory and require further validation in larger cohorts.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BCL2 (B-cell CLL/lymphoma 2) • MMP11 (Matrix Metallopeptidase 11) • SCUBE2 (Signal Peptide, CUB Domain And EGF Like Domain Containing 2)
    |
    ER positive • HER-2 negative • HER-2 expression • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Oncotype DX Breast Recurrence Score®Test
    24d
    Sentinel Lymph Node Positivity and Utility of Frozen Section Diagnosis following Neoadjuvant Therapy in Patients with Clinically Node-Negative, Hormone Receptor-Positive, HER2-Negative Breast Cancer. (PubMed, Ann Surg Oncol)
    In patients with cN0 HR+, HER2-negative breast cancer, SLN positivity after NACT varies and is more common in high-risk subgroups of this population. Frozen section has modest sensitivity overall and is more limited for the diagnosis of low-volume nodal disease. Use of frozen section may be warranted where avoiding reoperation is a priority.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • PGR positive • HR positive + HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    26d
    KEYNOTE-242: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=1155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab)
    1m
    CLEE011AIC01: A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=175, Completed, Novartis Pharmaceuticals | Recruiting --> Completed | N=550 --> 175
    Trial completion • Enrollment change • HEOR • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib)